ReViral

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Ingredients

ReViral appoints Alex Sapir as new CEO

Sapir will be based at North Carolina’s Research Triangle Park alongside the company’s new CMO, Seth Hetherington
Recruitment

ReViral appoints Dr Hetherington as Chief Medical Officer

The CMO appointment has been made as the company prepares its lead RSV candidate to enter phase II of clinical trials
Recruitment

ReViral announces appointment of new Chief Executive Officer

ReViral is an antiviral drug discovery and development company focused on novel antiviral treatments for diseases caused by the respiratory syncytial virus (RSV)
Subscribe now